In This Section

Program

Please Note: All session times for the AACR Virtual Meeting: Myeloma – Discovery to Therapy are U.S. Eastern Standard Time (EST).

Monday, April 26, 2021

Tuesday, April 27, 2021

MONDAY, APRIL 26, 2021

Session 1: Disease Progression from Precursor Conditions to Myeloma
Moderators: Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MAssachusetts, and Ola Landgren, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
10-11:20 a.m.

The genomic basis of smoldering multiple myeloma progression
Salomon Manier, University of Lille, Lille, France

Imaging based predictors of disease progression in early stages of monoclonal plasma cell disorders
Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, New York

How to manage smoldering myeloma?
María-Victoria Mateos, University of Salamanca, Salamanca, Spain

Panel Discussion

Break
11:20-11:35 a.m.
Session 2: Genomics and Epigenetics of Myeloma
Moderator: Brian Walker, Indiana University–Purdue University Indianapolis, Indianapolis, Indiana
11:35 a.m.-12:55 p.m.

Understanding multiple myeloma life history using whole-genome sequencing
Francesco Maura, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

Title to be announced
Constantine Mitsiades, Dana-Farber Cancer Institute, Boston, Massachusetts

The definition of high-risk disease
Faith E. Davies, NYU Langone Health, New York, New York

Panel Discussion

TuesDAY, APRIL 27, 2021

Session 3: Myeloma Microenvironment and Immunotherapy
Moderators: Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MASSACHUSETTS, and Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:20 a.m.

Title to be announced
Madhav V. Dhodapkar, Emory University, Atlanta, Georgia

Advances in adoptive cellular therapy for multiple myeloma
Eric L. Smith, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion

Break
11:20-11:35 a.m.
Session 4: Novel Therapeutics and Drug Resistance
Moderators: Paola Neri, University of Calgary, Calgary, Alberta, Canada, and Paula Rodríguez-Otero, University of Navarra, Pamplona, Spain
11:35 a.m.-12:55 p.m.

Targeting the BCL2 family in multiple myeloma
Lawrence H. Boise, Emory Winship Cancer Institute, Atlanta, Georgia

Targeted therapies in relapsed/refractory multiple myeloma
Marc S. Raab, Heidelberg University Hospital, Heidelberg, Germany

Treatment of lenalidomide refractory patients
Francesca Gay, University of Torino, Torino, Italy

Panel Discussion

Break
12:55-1:10 p.m.
Panel Discussion: Bench to Bedside – Application of Lessons Learned from COVID-19 to Clinical Trials and Drug Development in Myeloma
Moderator: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
1:10-2 p.m.

Kenneth C. Anderson
Daniel Auclair, Multiple Myeloma Research Foundation, Norwalk, Connecticut
Nicole J. Gormley, FDA Center for Drug Evaluation & Research, Silver Spring, Maryland
Craig L. Tendler, Johnson & Johnson Pharmaceutical R&D, New Brunswick, New Jersey